Business
PacBio Begins Commercialization of the Onso Short-Read Sequencing System
The Onso Platform Delivers Extraordinary Accuracy Which Creates New Possibilities for Research and Translational Sequencing Applications MENLO PARK, Calif.,
About this update from Pacific Biosciences Of California, Inc.
[{"type":"text","content":"The Onso Platform Delivers Extraordinary Accuracy Which Creates New Possibilities for Research and Translational Sequencing Applications\nMENLO PARK, Calif., Aug. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced that customer shipments of Onso short-read sequencing instruments will commence today. As previously announced, the Onso system is designed to provide extraordinary accuracy through its novel sequencing by binding (SBB) chemistry in a user-friendly and flexible benchtop platform.\n\n \n \n \n \n \n \n\n \n\"When we announced the Onso platform last year, I knew it would be a game changer for genomics,\" said Christian Henry, President and Chief Executive Officer of PacBio. \"We believe PacBio is the only company to offer both highly accurate, native short and native long-read sequencing technologies. As a result, we believe this uniquely positions us to offer more complete solutions to our customers' challenges and help researchers unlock novel insights in oncology and disease research, among other areas. I want to thank the Broad Institute of MIT and Harvard, Corteva Agriscience, and Weill Cornell Medicine for their invaluable feedback, helping us to improve this cutting-edge system and bring it to market.\"\n\"Over the last several months, we have tested out the Onso system in order to understand how high-quality sequence data can be used in the context of germline and somatic applications. We already have some novel findings and are excited to see where the platform goes from here,\" said Niall Lennon, Senior Director of Translational Genomics at Broad Institute of MIT and Harvard.\nWith Onso's potential to achieve Q40+ levels of accuracy (one error in 10,000 bases), we believe scientists will have the opportunity to gain more insight into ctDNA research applications like minimal residual disease (MRD) monitoring and other \"needle-in-haystack\" applications which require highly sensitive variant detection. This may ultimately allow researchers to detect rare variants missed by other short-read technologies.\n\"Since we started testing the Onso system across a range of different applications, my laboratory at Weill Cornell Medicine is seeing impressive data quality well above the industry norm of Q30,\" said Dr. Chris Mason. \"We've had ...